Positions

Selected Publications

Academic Article

Year Title Altmetric
2019 Corruption of neuroblastoma patient derived xenografts with human T cell lymphoma.  Journal of Pediatric Surgery.  54:2117-2119. 2019
2019 The presence of PIM3 increases hepatoblastoma tumorigenesis and tumor initiating cell phenotype and is associated with decreased patient survival.  Journal of Pediatric Surgery.  54:1206-1213. 2019
2018 Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report..  Neuro-Oncology.  20:132-142. 2018
2018 Adolescent and young adult oncology, version 2.2018: Clinical practice guidelines in oncology 2018
2017 Benefit Finding and Quality of Life in Caregivers of Childhood Cancer Survivors.  Cancer Nursing.  40:E28-E37. 2017
2015 Predictors of colorectal cancer surveillance among survivors of childhood cancer treated with radiation: A report from the Childhood Cancer Survivor Study.  Cancer.  121:1856-1863. 2015
2014 Barriers to the Use of Psychosocial Support Services Among Adolescent and Young Adult Survivors of Pediatric Cancer..  Journal of Adolescent and Young Adult Oncology.  3:112-116. 2014
2014 Adolescent and young adult oncology, version 2.2014. 2014
2014 Adolescent and young adult oncology, version 2.2014: Featured updates to the NCCN guidelines 2014
2014 Antimüllerian hormone as a measure of reproductive function in female childhood cancer survivors..  Fertility and Sterility.  101:227-231. 2014
2012 Adolescent and young adult oncology clinical practice guidelines in oncology 2012
2012 Toward a safer cure for low-risk Hodgkin lymphoma in children 2012
2012 Social, demographic, and medical influences on physical activity in child and adolescent cancer survivors.  Journal of Pediatric Psychology.  37:198-208. 2012
2009 Predictors of inactive lifestyle among adult survivors of childhood cancer.  Cancer.  115:1984-1994. 2009
2006 Visual complications in childhood cancer survivors: A Childhood Cancer Survivor Study report..  Journal of Clinical Oncology.  24:9006. 2006

Chapter

Year Title Altmetric
2018 Epidemiology of Childhood Cancer.  1-20. 2018

Principal Investigator On

Investigator On

  • A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AAML 1031 - A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib (NSC# 681239) and Sorafenib (BAY 43-9006, NSC# 724772) for Patients with High Allelic Ratio FLT2/ITD  awarded by CHILDREN'S ONCOLOGY GROUP
  • AAML 1031 - Bayer  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ALTE11C2 Study - Health Effects after Antracycline and Radiation Therapy (HEART) - Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • ALTE11C2 Study – Health Effects After Antracycline and Radiation Therapy (HEART) – Dexazoxane and Prevention of Antracycline-Related Cardiomyopathy  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION  awarded by CHILDREN'S ONCOLOGY GROUP
  • Adaptive Immunity and Persistent SARS-CoV-2 Replication  awarded by National Cancer Institute/NIH/DHHS
  • BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CCOP Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • COG Per Case Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase II Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • CTSU: Phase ll Supplemental Payments (N02-CM-62212)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Cookies for Kids' Cancer Phase 1 Supplemental  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Fungal Biomarkers for Diagnosis and Response to Therapy for Pediatric Candidemia  awarded by Duke University
  • Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas  awarded by H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
  • NIH COG Phase I Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Novel Methods to Detect Gene-Environment Interactions in Treatment-Related Brain Tumors Among Childhood Cancer Survivors  awarded by University of Wisconsin-Milwaukee
  • PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma  awarded by CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
  • Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Per Case Reimbursement: COG NCORP Research Base  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC.
  • Private Grant  awarded by UNITED THERAPEUTICS CORPORATION
  • Private Grant  awarded by Bayer AG
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC
  • Private Grant  awarded by EISAI, INC.
  • Project EveryChild APEC14B1  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Project Everychild APEC14B1  awarded by CHILDREN'S ONCOLOGY GROUP
  • Reduced Burden Of Oncology Therapy in Advanced B-Cell Lymphoma (REBOOT ABLY) in Children, Adolescents, and Young Adults with CD20+ Mature B-Cell Lymphoma  awarded by NEW YORK MEDICAL COLLEGE
  • St. Baldrick's Foundation Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • St. Baldricks Fdn Supplemental Reimbursement  awarded by CHILDREN'S HOSPITAL (PHILADELPHIA)
  • Transforming Pediatric Oncology Healthcare Through Family Navigation  awarded by UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION

    • Teaching Activities

  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408M - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2020) 2020
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2020) 2020
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2019) 2019
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2019) 2019
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2018) 2018
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2018) 2018
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2017) 2017
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • 52-408 - PEDIATRIC HEMATOLOGY/ONCOLOGY (Fall Term 2016) 2016
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2016) 2016
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015) 2015
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2015) 2015
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2014) 2014
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Spring Term 2013) 2013
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2011) 2011
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2010) 2010
  • PCL2225 - HEMATOLOGY/ONCOLOGY (Fall Term 2009) 2009
  • PCL2225 - HEMATOLOGY / ONCOLOGY (Fall Term 2008) 2008

    • Education And Training

  • Vanderbilt University Medical Center, Residency
  • UAB Hospital, Postdoctoral Fellowship
  • Doctor of Medicine, University of South Carolina System : Columbia 2000

    • Full Name

  • Kimberly Whelan